Development and First Use of the Patient’s Qualitative Assessment of Treatment (PQAT) Questionnaire in Type 2 Diabetes Mellitus to Explore Individualised Benefit–Harm of Drugs Received During Clinical Studies
Sign Up to like & getrecommendations! Published in 2019 at "Drug Safety"
DOI: 10.1007/s40264-019-00877-4
Abstract: Introduction Individualised benefit–harm assessments can help identify patient-perceived benefits and harms of a treatment, and associated trade-offs that may influence patients’ willingness to use a treatment. This research presents the first use of a patient-reported… read more here.
Keywords: pqat; benefit harm; treatment; use patient ... See more keywords
Renal Outcomes and the Relative Benefit and Harm of Intensive Treatment of Hypertension.
Sign Up to like & getrecommendations! Published in 2018 at "Journal of the American College of Cardiology"
DOI: 10.1016/j.jacc.2018.04.090
Abstract: We read with interest the paper by Philips et al. [(1)][1] reporting the effect of baseline 10-year cardiovascular disease risk on primary outcome events and all-cause serious adverse events in SPRINT (Systolic Blood Pressure Intervention Trial).… read more here.
Keywords: benefit harm; renal outcomes; intensive treatment; outcomes relative ... See more keywords
Benefit–harm analysis of azithromycin for the prevention of acute exacerbations of chronic obstructive pulmonary disease
Sign Up to like & getrecommendations! Published in 2021 at "Thorax"
DOI: 10.1136/thoraxjnl-2021-217962
Abstract: Background Low-dose oral azithromycin therapy is recommended as a preventive treatment for acute exacerbations of COPD. However, the overall benefit–harm balance of this treatment has not been well studied. Methods A probabilistic Markov model of… read more here.
Keywords: acute exacerbations; benefit; benefit harm; analysis ... See more keywords
Rejoinder to Dr Vickers
Sign Up to like & getrecommendations! Published in 2022 at "Clinical Trials"
DOI: 10.1177/17407745211068548
Abstract: We thank Dr Vickers for his thoughtful commentary. Dr Vickers argues that if a benefit–harm metric includes absolutely every aspect of the decision, then there is no clinically relevant difference, and even for the smallest… read more here.
Keywords: benefit harm; net benefit; evidence; benefit ... See more keywords
Optimal risk thresholds for prescribing statins as primary prevention of cardiovascular disease in Iranian general population: a benefit-harm modelling study
Sign Up to like & getrecommendations! Published in 2024 at "BMC Cardiovascular Disorders"
DOI: 10.1186/s12872-024-04242-x
Abstract: The use of statins for the primary prevention of cardiovascular diseases (CVD) is associated with various beneficial outcomes, alongside certain undesirable effects. This study aims to determine optimal risk thresholds above which statin therapy yields… read more here.
Keywords: benefit harm; risk thresholds; primary prevention; risk ... See more keywords
Beyond prediction intervals in meta-analysis: reporting the expected proportion of comparable studies with clinically relevant benefit or harm.
Sign Up to like & getrecommendations! Published in 2025 at "BMC medical research methodology"
DOI: 10.1186/s12874-025-02733-9
Abstract: In a meta-analysis where the effect size varies substantially between studies it is important to report the extent of the variation. Critically, we want to know if the treatment is always helpful or sometimes harmful.… read more here.
Keywords: meta analysis; benefit harm; expected proportion; proportion comparable ... See more keywords